title: Primary lymphoma of the stomach: three-year results of a prospective multicenter study. The German Multicenter Study Group on GI-NHL.
abstract: BACKGROUND
  In October 1992, an ongoing prospective study on primary gastrointestinal (GI) lymphoma was initiated to evaluate histological features, sites of involvement, and management.
  
  
  METHODS
  Until May 1996, 352 patients were enrolled, with 279 being evaluable for clinical features (208 patients presented with primary gastric lymphoma). Standardized diagnostic workup included central histologic review and endoscopic and radiologic evaluation of the complete GI tract. Primary surgery or conservative management depended on the physician's decision, followed by radiotherapy with or without chemotherapy. Treatment outcome is evaluable in 122 patients with gastric lymphoma.
  
  
  RESULTS
  In 279 evaluable patients, the distribution of NHL was as follows: stomach 74.6%, small bowel 8.6%, ileocoecal region 6.5%, multilocal GI involvement 6.8%. In gastric lymphoma, low-grade NHLs accounted for 39%. Of the remaining high-grade NHLs, 36.1% showed simultaneous low-grade components, thus being also of MALT origin. Of 208 patients with gastric NHL, 71.1% were classified as stage I and II1. CCR rate in stomach lymphoma is significantly higher compared to those of the small bowel, whereas involvement of multiple GI organs has the worst prognosis. So far only 7 patients with gastric NHL in stages I and II presented with progressive disease or relapse. Over all stages there seems to be no difference in therapeutic outcome in surgically or conservatively treated patients. Even after R0-resection in limited stages patients appear to have no better outcome.
  
  
  CONCLUSIONS
  The value of surgery in treatment of primary gastric lymphoma--as favored by most authors--should be reexamined.
authors.affiliation: Department of Medicine, University of Münster, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Koch
authors.forename: B
authors.initials: B
authors.lastname: Grothaus-Pinke
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: N
authors.initials: N
authors.lastname: Willich
authors.forename: B
authors.initials: B
authors.lastname: Reers
authors.forename: F
authors.initials: F
authors.lastname: del Valle
authors.forename: H
authors.initials: H
authors.lastname: Bodenstein
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
authors.forename: E
authors.initials: E
authors.lastname: Möller
authors.forename: J
authors.initials: J
authors.lastname: Kocik
authors.forename: R
authors.initials: R
authors.lastname: Parwaresch
authors.forename: M
authors.initials: M
authors.lastname: Tiemann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome